GSA Capital Partners LLP Boosts Holdings in Sarepta Therapeutics, Inc. $SRPT

GSA Capital Partners LLP boosted its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 242.2% in the 4th quarter, Holdings Channel reports. The institutional investor owned 70,371 shares of the biotechnology company’s stock after buying an additional 49,806 shares during the quarter. GSA Capital Partners LLP’s holdings in Sarepta Therapeutics were worth $1,514,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Larson Financial Group LLC boosted its stake in Sarepta Therapeutics by 82.5% during the fourth quarter. Larson Financial Group LLC now owns 1,882 shares of the biotechnology company’s stock worth $41,000 after buying an additional 851 shares during the period. Handelsbanken Fonder AB lifted its position in shares of Sarepta Therapeutics by 22.4% during the fourth quarter. Handelsbanken Fonder AB now owns 31,115 shares of the biotechnology company’s stock worth $670,000 after purchasing an additional 5,700 shares during the last quarter. Profund Advisors LLC lifted its position in shares of Sarepta Therapeutics by 96.1% during the fourth quarter. Profund Advisors LLC now owns 76,224 shares of the biotechnology company’s stock worth $1,640,000 after purchasing an additional 37,350 shares during the last quarter. Allworth Financial LP lifted its position in shares of Sarepta Therapeutics by 310.1% during the fourth quarter. Allworth Financial LP now owns 7,395 shares of the biotechnology company’s stock worth $159,000 after purchasing an additional 5,592 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund lifted its position in shares of Sarepta Therapeutics by 9.1% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 24,000 shares of the biotechnology company’s stock worth $516,000 after purchasing an additional 2,000 shares during the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Stephen Mayo sold 7,239 shares of the company’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $17.02, for a total value of $123,207.78. Following the completion of the sale, the director directly owned 1,765 shares of the company’s stock, valued at $30,040.30. This represents a 80.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 6.90% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

SRPT has been the subject of several research analyst reports. Loop Capital set a $25.00 target price on Sarepta Therapeutics in a research report on Tuesday, March 3rd. HC Wainwright reiterated a “sell” rating on shares of Sarepta Therapeutics in a research report on Thursday, April 16th. Barclays initiated coverage on Sarepta Therapeutics in a research report on Wednesday, January 28th. They set an “equal weight” rating and a $20.00 target price for the company. Oppenheimer reiterated an “outperform” rating and set a $37.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, March 19th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $30.00 target price on shares of Sarepta Therapeutics in a research report on Tuesday, March 3rd. Nine investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and six have given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $27.71.

Sarepta Therapeutics Stock Up 2.9%

NASDAQ:SRPT opened at $17.12 on Thursday. Sarepta Therapeutics, Inc. has a 1-year low of $10.41 and a 1-year high of $44.14. The company has a 50-day moving average of $20.02 and a 200 day moving average of $20.00. The firm has a market cap of $1.81 billion, a PE ratio of -17.83, a price-to-earnings-growth ratio of 0.19 and a beta of 0.26. The company has a debt-to-equity ratio of 0.56, a current ratio of 4.63 and a quick ratio of 2.62.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $3.16 earnings per share for the quarter, topping analysts’ consensus estimates of $0.98 by $2.18. Sarepta Therapeutics had a negative net margin of 2.94% and a positive return on equity of 7.56%. The company had revenue of $730.80 million during the quarter, compared to analyst estimates of $474.16 million. During the same period in the prior year, the firm earned ($3.42) earnings per share. The firm’s revenue for the quarter was down 1.9% compared to the same quarter last year. As a group, research analysts anticipate that Sarepta Therapeutics, Inc. will post 3.69 EPS for the current fiscal year.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.